Raras
Buscar doenças, sintomas, genes...
Doença de Kawasaki
ORPHA:2331CID-10 · M30.3CID-11 · 4A44.5OMIM 611775DOENÇA RARA

A doença de Kawasaki (DK) é uma vasculite febril, sistêmica e autolimitada que afeta crianças e é caracterizada por inflamação nos vasos de médio calibre associada a aneurismas arteriais coronários (AAC) que podem ser fatais quando não tratados. A DK é a causa mais comum de doença cardíaca adquirida em crianças nos países desenvolvidos e é um fator de risco para doença cardíaca isquêmica na idade adulta.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A doença de Kawasaki (DK) é uma vasculite febril, sistêmica e autolimitada que afeta crianças e é caracterizada por inflamação nos vasos de médio calibre associada a aneurismas arteriais coronários (AAC) que podem ser fatais quando não tratados. A DK é a causa mais comum de doença cardíaca adquirida em crianças nos países desenvolvidos e é um fator de risco para doença cardíaca isquêmica na idade adulta.

Pesquisas ativas
17 ensaios
63 total registrados no ClinicalTrials.gov
Publicações científicas
9.403 artigos
Último publicado: 2026

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Adolescent
+ adult, childhood, infancy
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: M30.3
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

❤️
Coração
7 sintomas
🫃
Digestivo
4 sintomas
👁️
Olhos
3 sintomas
🩸
Sangue
3 sintomas
🧬
Pele e cabelo
2 sintomas
🫘
Rins
1 sintomas

+ 23 sintomas em outras categorias

Características mais comuns

90%prev.
Erupção cutânea
Muito frequente (99-80%)
90%prev.
Proteinúria
Muito frequente (99-80%)
90%prev.
Conjuntivite
Muito frequente (99-80%)
90%prev.
Faringite recorrente
Muito frequente (99-80%)
90%prev.
Eritema palmoplantar
Muito frequente (99-80%)
90%prev.
Vasculite
Muito frequente (99-80%)
46sintomas
Muito frequente (8)
Frequente (21)
Ocasional (17)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 46 características clínicas mais associadas, ordenadas por frequência.

Erupção cutâneaSkin rash
Muito frequente (99-80%)90%
ProteinúriaProteinuria
Muito frequente (99-80%)90%
ConjuntiviteConjunctivitis
Muito frequente (99-80%)90%
Faringite recorrenteRecurrent pharyngitis
Muito frequente (99-80%)90%
Eritema palmoplantarPalmoplantar erythema
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico9.403PubMed
Últimos 10 anos200publicações
Pico2026120 papers
Linha do tempo
2026Hoje · 2026🧪 1985Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado3
3Fase 32
2Fase 21
1Fase 11
·Pré-clínico13
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença de Kawasaki

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

12 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

63 ensaios clínicos encontrados, 17 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
5.125 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 5.125

#1

Hemolytic anemia post high-dose IVIG in Kawasaki disease: Impact of inflammation and iron status on outcomes.

Pediatrics international : official journal of the Japan Pediatric Society2026

As an initial therapy for Kawasaki disease, high-dose intravenous immunoglobulin (IVIG) is recommended. It is known that intravenous immunoglobulins are associated with hemolytic anemia. However, little is known about hemolytic anemia in Kawasaki disease (KD) patients treated with IVIG. This study was designed to investigate the incidence of hemolytic anemia and factors associated with the development of hemolysis in KD patients treated with IVIG. We performed a 3-year single-center prospective study enrolling 105 KD patients treated with IVIG from January 2021 to May 2024 at Chungnam National University Hospital. Clinical characteristics and laboratory data were collected and analyzed. Hemolytic anemia was defined as a drop in hemoglobin levels or worsening of anemia after IVIG infusion greater than or equal to 2 g/dL with supporting biochemical studies. Fifteen percent of KD patients (16/105) developed hemolytic anemia post-IVIG. Increased IVIG dose, prolonged duration of fever, high pre- and post-IVIG white blood cell counts, non-O blood groups, NT-ProBNP, and refractory KD were significantly associated with the hemolysis group (p < 0.05). However, erythrocyte sedimentation rate (ESR), C-reactive protein, and iron deficiency anemia parameters were not significant between the two groups. This study suggests that a non-O blood group, a higher cumulative IVIG dose, elevated NT-ProBNP levels, and increased white blood cell counts may be associated with an increased risk of hemolysis following IVIG therapy. These findings are hypothesis-generating and support the need for closer monitoring and further investigation in larger, controlled studies.

#2

[Effectiveness and safety of rivaroxaban in pediatric patients with coronary artery diseases: a case series study].

Zhonghua er ke za zhi = Chinese journal of pediatrics2026 Mar 14

Objective: To evaluate the Effectiveness and safety of rivaroxaban in combination with antiplatelet therapy for treating pediatric coronary artery diseases. Methods: This case series study included 84 pediatric patients with coronary artery diseases who received antiplatelet therapy plus rivaroxaban at the Children's Hospital of Fudan University from January 2024 to October 2025. Clinical characteristics, rivaroxaban doses, rivaroxaban plasma concentration, anti-factor Ⅹa activity, and therapeutic outcomes were collected and analyzed. Linear regression was used to assess the relationship between plasma concentration and anti-factor Ⅹa activity. Results: Among the 84 patients, 66 were male (79%) and 18 were female (21%). The age and body weight at rivaroxaban initiation was 86 (51, 129) months and 24 (15, 40) kg, respectively. The treatment duration with rivaroxaban was 305 (121, 460) d. The initial dose followed a 15.0 mg/d targeted regimen. Indications included Kawasaki disease with coronary artery lesions (82 patients, 98%) and status post coronary artery fistula occlusion (2 patients, 2%). During follow-up, no new thrombotic events were observed; however, 1 patient (1%) experienced a major adverse cardiovascular event. No major bleeding events occurred, while 4 patients (5%) developed clinically relevant non-major bleeding. Regarding dose adjustment, among the 69 children aged ≥24 months, 18 (26%) required adjustment with 30 unplanned adjustments. In contrast, among the 15 children aged <24 months, 10 children required adjustment with 16 unplanned adjustments. The rivaroxaban plasma concentration at 2-4 hours post-administration was 152 (107, 207) μg/L, corresponding to the rivaroxaban calibrated anti-factor Ⅹa activity of 126 (80, 186) μg/L. A strong linear correlation was observed between plasma concentration and anti-factor Ⅹa activity (plasma concentration=1.049×anti-factor Ⅹa activity+13.52, R²=0.919, P<0.001). Conclusions: The 15.0 mg/d targeted rivaroxaban regimen demonstrates favorable effectiveness and safety in Chinese children aged 24 months or older with coronary artery diseases. However, for children younger than 24 months, regular monitoring of rivaroxaban-calibrated anti-factor Ⅹa activity is recommended to guide individualized dosing. 目的: 总结利伐沙班治疗儿童冠状动脉疾病的临床经验,评估其在抗血小板联合抗凝治疗背景下的有效性和安全性。 方法: 病例系列研究。选择2024年1月至2025年10月在复旦大学附属儿科医院接受抗血小板联合利伐沙班治疗的84例冠状动脉疾病患儿为研究对象,回顾性分析其临床资料、血药浓度、抗凝监测结果及治疗结局。构建线性回归模型,分析血药浓度与抗Ⅹa因子活性之间的相关性。 结果: 共纳入84例患儿,男66例(79%)、女18例(21%),开始使用利伐沙班时的年龄为86(51,129)月龄,体重为24(15,40)kg,利伐沙班使用时间为305(121,460)d。利伐沙班初始剂量参考15.0 mg/d等效的剂量优化方案。适应证包括川崎病合并冠状动脉病变82例(98%),冠状动脉瘘堵闭术后2例(2%)。研究期间发生1例(1%)严重心血管不良事件,未出现新发血栓,未见严重出血事件,4例(5%)发生临床相关非严重出血事件。69例≥24月龄组患儿中,18例(26%)需调整剂量,发生30次计划外调整;15例<24月龄组患儿中,10例需调整剂量,发生16次计划外调整。给药后2~4 h血药浓度为152(107,207)μg/L,利伐沙班校正的抗Ⅹa因子活性为126(80,186)μg/L。血药浓度和利伐沙班校正的抗Ⅹa因子活性呈良好的线性相关(血药浓度=利伐沙班校正的抗Ⅹa因子活性×1.049+13.52,R2=0.919,P<0.001)。 结论: 15.0 mg/d等效的利伐沙班剂量优化方案在≥24月龄冠状动脉疾病患儿中具有良好的有效性和安全性。对于<24月龄患儿,建议结合利伐沙班校正的抗Ⅹa因子活性监测进行个体化剂量调整。.

#3

Comprehensive machine learning for identifying platelet-associated diagnostic biomarkers and immune landscape in Kawasaki disease.

Translational pediatrics2026 Feb 28

Kawasaki disease (KD) is an acute, self-limited febrile illness primarily affecting children under 5 years of age. Platelets play a crucial dual role in both hemostasis and inflammatory/immune responses, contributing to vascular damage in diseases such as KD, making their study essential for the diagnosis and treatment of KD. Therefore, this study aimed to identify platelet-related diagnostic biomarkers, construct a machine learning-based diagnostic model, and computationally characterize their associated immune features, pathway activities, and regulatory networks in KD. This study integrated transcriptomic datasets from 4 KD cohorts in the Gene Expression Omnibus database (training set: GSE68004/GSE73461; validation set: GSE100154/GSE63881). Platelet-associated differentially expressed genes were screened through differential analysis and Weighted Gene Co-expression Network Analysis. Four diagnostic biomarkers were identified via cross-validation using least absolute shrinkage and selection operator, random forest, and eXtreme Gradient Boosting algorithms, with model efficacy assessed through Receiver operating characteristic curve analysis. Immune infiltration characteristics were analyzed using single sample Gene Set Enrichment Analysis (GSEA) and CIBERSORT, pathway enrichment was performed via GSEA, molecular subtypes were classified using the non-negative Matrix Factorization algorithm, and miRNA and transcription factor (TF) regulatory networks were predicted through miRNet/NetworkAnalyst. We identified 4 platelet-associated biomarkers (CD63, F5, STXBP2, and SERPINA1) with exceptional diagnostic power. These genes orchestrate KD pathogenesis through dysregulated coagulation (F5), immune hyperactivation (CD63/STXBP2), and vascular injury (SERPINA1), further validated by their strong correlations with neutrophil infiltration and ribosome pathway suppression. Molecular subtyping revealed distinct immune-endotypes (e.g., neutrophil-dominant vs. natural killer-cell-enriched clusters), while regulatory network analysis uncovered has-miR-155-5p and TF hubs (SMAD5/SAP30/PHF8) as potential master regulators. This study utilized platelet-associated biomarkers to establish a machine learning-based diagnostic model for KD and elucidated their pathogenic roles in immune dysregulation and vascular injury, thereby laying the foundation for improved diagnosis and targeted therapy in KD.

#4

Linkage between IL-23 and coronary arterial lesions in pediatric patients with Kawasaki disease.

Frontiers in pediatrics2026

Coronary artery lesions (CALs) in Kawasaki disease (KD) are thought to arise from aberrant immune activation and an amplified inflammatory cascade triggered by an unidentified etiologic factor. Interleukin-23 (IL-23)-a pivotal modulator of chronic inflammatory responses and immune-mediated vascular damage-has lately garnered interest regarding its putative role in cardiovascular pathological processes. To explore the correlation between circulating IL-23 concentrations and the occurrence of CALs in pediatric patients with KD. Peripheral blood samples were obtained from 103 pediatric patients with KD prior to administration of intravenous immunoglobulin. Using Enzyme-Linked Immunosorbent Assay (ELISA), we quantified circulating cytokine levels in a total of 211 study participants, who were stratified into four distinct cohorts: 47 KD cases with coronary artery lesions, 56 cases without vascular involvement, 58 febrile controls, and 50 healthy controls. Serum IL-23 concentrations were markedly elevated in children with KD [279.69 pg/mL (132.67-693.32)] compared with both febrile controls [161.02 pg/mL (81.50-338.60)] and healthy controls [132.41 pg/mL (61.74-274.28)] (P < 0.001), indicating a disease-specific elevation. Among KD patients, 47 (45.63%) developed CALs. The KD individuals presenting with CAL (KD-CALs) group exhibited markedly higher IL-23 levels [395.76 pg/mL (221.62-1,217.19)] compared with KD individuals without CAL (KD-NCALs) [222.81 pg/mL (100.18-388.58), P < 0.001], accompanied by higher Erythrocyte Sedimentation Rate (ESR) and increased Interleukin-6 (IL-6), matrix metalloproteinase-1 (MMP-1), vascular endothelial growth factor (VEGF) levels. IL-23 displayed significant positive associations with multiple inflammatory indices, including white blood cell count (WBC), C-reactive protein (CRP), IL-6, Interleukin-10 (IL-10), Interleukin-17A (IL-17A), MMP-1, and VEGF. Receiver operating characteristic (ROC) analysis showed that IL-23 effectively discriminated KD from controls [area under the curve (AUC) = 0.71, cutoff = 202.3 pg/mL, sensitivity = 66.0%, specificity = 68.0%] and KD-CAL from KD-nCAL (AUC = 0.69, cutoff = 661.2 pg/mL, sensitivity = 42.6%, specificity = 87.5%). Elevated serum IL-23 is associated with heightened inflammatory activity and the presence of coronary artery lesions in KD, suggesting that IL-23 may contribute to CAL pathogenesis and represent a potential biomarker of vascular involvement.

#5

Kawasaki disease vs. MIS-C in a child with congenital coronary artery anomaly: a case report.

Frontiers in pediatrics2026

Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C), associated with SARS-CoV-2 infection share overlapping clinical and laboratory features, making differential diagnosis particularly challenging during the COVID-19 pandemic. Accurate distinction is essential due to differences in pathophysiology, management strategies, and cardiovascular outcomes. We report the case of a 7-year-old boy presenting with prolonged fever, mucocutaneous manifestations, arthritis, and elevated inflammatory markers following SARS-CoV-2 exposure. The clinical course demonstrated features compatible with both incomplete Kawasaki disease and MIS-C. Laboratory findings and cardiac biomarkers showed a mixed profile, while echocardiography and coronary imaging revealed the development of coronary artery aneurysms. Notably, a complex congenital coronary artery anomaly was incidentally identified during coronary evaluation. Although such anomalies are not considered independent risk factors for coronary aneurysm formation, their presence may complicate the interpretation of coronary findings in the setting of systemic inflammation. The patient showed a rapid and sustained clinical response to systemic glucocorticoid therapy without intravenous immunoglobulin administration; however, coronary artery aneurysms subsequently developed. This case highlights the diagnostic and therapeutic challenges at the interface of KD and MIS-C and underscores the importance of an integrated, individualized approach that incorporates clinical evolution, laboratory data, and detailed coronary assessment.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC7.824 artigos no totalmostrando 196

2026

Identification of Serum BST1 as a Biomarker to Predict Coronary Artery Lesions in Children with Kawasaki Disease Based on 4D-DIA Quantitative Proteomics.

Journal of inflammation research
2026

Predicting recalcitrant hyperinflammatory disease course in children with Kawasaki disease and MIS-C.

Pediatric rheumatology online journal
2026

Change in Seasonality of Kawasaki Disease After the COVID-19 Pandemic: A 10-year Survey in Shiga, Japan (2015-2024).

The Pediatric infectious disease journal
2026

Incomplete Kawasaki Disease Presenting With Coronary Artery Aneurysms in a 2.5-Month-Old Infant: A Case Report.

Cureus
2026

An interpretable machine learning model for early risk stratification of medium-to-giant coronary artery aneurysm in Kawasaki disease: development and external validation.

Pediatric research
2026

Nomogram for Predicting Regression of Persistent Coronary Artery Aneurysms in Kawasaki Disease: A Three-year Follow-up Cohort Study in Southwest China.

Journal of inflammation research
2026

Valvulitis Matters: Linking Mitral Regurgitation to Inflammatory Burden in Kawasaki Disease.

Korean circulation journal
2026

Targeting STAT3 pathway attenuates macrophages inflammation and cardiovascular injury in a model of Kawasaki disease.

Scientific reports
2026

Retrospective study: clinical analysis of Kawasaki disease complicated with macrophage activation syndrome.

Italian journal of pediatrics
2026

The quality and reliability of Kawasaki disease-related short videos on TikTok and Bilibili: a cross-platform content analysis using GQS, mDISCERN, and JAMA benchmarks.

Italian journal of pediatrics
2026

Dynamic assessment of myocardial contractile dysfunction and its recovery after IVIG treatment in a murine model of Kawasaki disease using high-resolution speckle-tracking echocardiography.

Frontiers in cardiovascular medicine
2026

Fatal incomplete Kawasaki disease in a six-month-old infant from Ethiopia: a case report : Author.

BMC pediatrics
2026

Prolonged Fever as a Predictor of Coronary Artery Aneurysms Among Children With Kawasaki Disease in North India.

The Pediatric infectious disease journal
2026

Performance of Kawasaki Disease Risk Scores in a 30-Year Regional Spanish Cohort.

Pediatric cardiology
2025

[Kawasaki Disease and Pediatric Multisystem Inflammatory Syndrome in the Aftermath of the Pandemic].

Andes pediatrica : revista Chilena de pediatria
2026

Infliximab therapy in a child with Kawasaki disease 2 weeks after receiving rotavirus vaccination.

Pediatrics international : official journal of the Japan Pediatric Society
2026

Hemolytic anemia post high-dose IVIG in Kawasaki disease: Impact of inflammation and iron status on outcomes.

Pediatrics international : official journal of the Japan Pediatric Society
2026

The Potential Role of Endothelial Cells in the Pathophysiology, Diagnosis, and Management of Acute Kawasaki Disease.

CJC open
2026

A Bibliometric Analysis of Research Productivity on Kawasaki Disease in Southeast Asia: Trend and Socioeconomic Drivers.

Acta medica Philippina
2026

[Effectiveness and safety of rivaroxaban in pediatric patients with coronary artery diseases: a case series study].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2026

Minimal correlation but complementary diagnostic utility for plasma cell-free RNA and proteins.

Communications medicine
2026

Intravenous immunoglobulin remodels innate immune cell communication and induces differential autophagy pathways in Kawasaki disease.

Frontiers in immunology
2026

Highlights on the Contribution of Gut Microbiota to Immune-Mediated Diseases in Childhood.

Mediterranean journal of hematology and infectious diseases
2026

Kawasaki disease shock syndrome in Korean children.

Clinical and experimental rheumatology
2026

Comprehensive machine learning for identifying platelet-associated diagnostic biomarkers and immune landscape in Kawasaki disease.

Translational pediatrics
2026

Linkage between IL-23 and coronary arterial lesions in pediatric patients with Kawasaki disease.

Frontiers in pediatrics
2026

Predictive value for intravenous immunoglobulin resistance of Kobayashi and Kawanet scores in 722 children with Kawasaki disease across diverse ethnic backgrounds (KIWI study): an international cohort study.

EClinicalMedicine
2026

Intravenous Immunoglobulin Resistant Incomplete Kawasaki Disease in a 4-Month-Old Infant: A Case Report.

Clinical case reports
2026

Oxidative stress-related genes in Kawasaki disease: a multi-omics Mendelian randomization study.

Italian journal of pediatrics
2026

2016 sJIA-MAS criteria and a step-up therapeutic approach in KD-MAS: insights from a combined cohort and literature review.

RMD open
2026

Midterm outcomes of coronary artery bypass grafting for Kawasaki disease in children: A multicenter retrospective study in China.

Chinese medical journal
2026

Phillyrin alleviates Kawasaki disease-induced lung inflammation by inhibiting platelet production through the NLRP3/IL-1β/NF-E2 signaling pathway.

Chinese medicine
2026

Dense Concentric Calcification in Kawasaki Disease With Early Graft Failure Successfully Treated With Rotatripsy-Assisted Angioplasty.

JACC. Case reports
2026

The diagnostic accuracy of CC chemokine ligand 23 for Kawasaki disease.

Frontiers in immunology
2026

Natural history of coronary aneurysms associated with Noonan's syndrome.

Journal of cardiology cases
2026

Novel biomarker-based prediction model for coronary artery lesions in Kawasaki disease.

BMC pediatrics
2026

Prenatal and postnatal risk factors associated with Kawasaki disease up to 3 years of age.

Scientific reports
2026

An abnormal immune response masquerading as infectious conditions.

SAGE open medical case reports
2026

Kawasaki disease vs. MIS-C in a child with congenital coronary artery anomaly: a case report.

Frontiers in pediatrics
2026

A nomogram for predicting Kawasaki Disease in acutely febrile children with liver injury.

European journal of pediatrics
2026

The Educational Value of Simulated Electronic Health Records in Pharmacy Education: Impacts on Clinical Reasoning, Interprofessional Perceptions, and ICT Literacy.

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
2026

Comprehensive immune repertoire profiling reveals distinct characteristics in Kawasaki disease and a mouse model.

Journal of immunology (Baltimore, Md. : 1950)
2026

Age-specific Association of Serum Albumin with Immunoglobulin Resistance and Coronary Artery Involvement in Kawasaki Disease.

Pediatric cardiology
2026

Changes in Serum Levels of NINJ1 and HMGB1 in Children with Kawasaki Disease and Their Clinical Significance.

Biomedicines
2026

Development of a Predictive Model for Cardiac Dysfunction in MIS-C Patients Utilizing Laboratory Biomarkers.

Children (Basel, Switzerland)
2026

Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial.

The lancet. Diabetes &amp; endocrinology
2026

Kawasaki Disease and the Importance of Family History.

JACC. Case reports
2026

Multimodality Approach to Coronary Ischemic Testing in Pediatric Patients: A Scientific Statement From the American Heart Association.

Journal of the American Heart Association
2026

SESN2 as a Novel Diagnostic and Prognostic Biomarker for Kawasaki Disease and Coronary Artery Lesions.

Journal of inflammation research
2025

Serum procalcitonin as a predictor of intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.

Annals of pediatric cardiology
2025

Prediction of Kawasaki disease coronary artery lesions in the Japan Environment and Children's Study.

Annals of pediatric cardiology
2026

Identification of programmed cell death and mitochondria correlated biomarkers for Kawasaki disease by integrated bioinformatics and machine-learning algorithms with RT-qPCR verification.

Frontiers in genetics
2026

Optical coherence tomography-derived coronary vessel wall abnormalities in adults long after Kawasaki disease.

PloS one
2026

Multiomics approaches in Kawasaki disease: insights into pathogenesis and emerging directions for diagnosis and treatment.

Clinical and experimental pediatrics
2026

Long noncoding RNA SRRM2-AS1 mediates coronary artery damage in Kawasaki disease by promoting endothelial-to-mesenchymal transition.

Clinical and experimental medicine
2026

Kawasaki Disease in a Child With Trisomy 18 Treated With Initial Combination Therapy, Including Cyclosporine.

Case reports in pediatrics
2026

Did the COVID-19 pandemic change the Kawasaki disease phenotype? Observations from the International Kawasaki Disease Registry.

Pediatric cardiology
2026

Kawasaki Disease-Associated Pancreatitis in an Adolescent: A Case Report and Literature Review.

Pediatric reports
2026

Incomplete Kawasaki disease with multivessel giant coronary aneurysms and refractory thrombosis in an infant; a case report.

European heart journal. Case reports
2026

The role of microRNAs in Kawasaki disease: a systematic review.

European journal of pediatrics
2026

Protective Effects of Jiawei Baihu Tang in Kawasaki Disease: Omics Analysis and Mechanistic Exploration.

Cardiovascular drugs and therapy
2026

Resveratrol ameliorates myocardial injury and inflammatory response and cell apoptosis in Kawasaki disease rats by activating the Nrf2/HO-1 pathway.

Journal of cardiothoracic surgery
2026

Favorable coronary outcomes following IL-6 blockade with tocilizumab in IVIG-resistant kawasaki disease: a case series.

Frontiers in immunology
2026

Systemic Arterial Aneurysms With Limb Ischemia in a 3-Month-Old Infant: An Unusual Presentation of Incomplete Kawasaki Disease.

Sage open pediatrics
2026

Predictors of Intravenous Immunoglobulin Non-Responsiveness in Children With Kawasaki Disease.

Immunity, inflammation and disease
2026

Assessing Seroprevalence and Infection Dynamics of Oncogenic Gammaherpesviruses in South African Paediatric Patients Presenting with Inflammatory Conditions.

International journal of molecular sciences
2026

Cutaneous Clues in Kawasaki Disease: Clinical Implications and Differential Diagnosis with Multisystem Inflammatory Syndrome in Children.

Journal of clinical medicine
2026

Predicting the Need for Infliximab in Kawasaki Disease Using N-Terminal Pro-Brain Natriuretic Peptide at Diagnosis.

Pediatric cardiology
2026

Coronary Artery Brightness on Echocardiography as a Novel Marker in Kawasaki Disease - Machine Learning-Based Cluster Analysis.

Circulation reports
2026

Characterization of the oral microbiota of Kawasaki disease patients by metagenomic analysis: A pilot study.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
2026

Grisel's syndrome as an early manifestation of Kawasaki disease preceding Kawasaki disease shock syndrome: a case report.

BMC cardiovascular disorders
2025

Evaluating the quality and reliability of Kawasaki disease-related content on TikTok and Bilibili: a cross-sectional study.

Frontiers in public health
2026

A nomogram for predicting the risk of persistent coronary artery aneurysms in children with Kawasaki disease: a retrospective study.

Frontiers in cardiovascular medicine
2026

Application of 3T contrast-enhanced Dixon water-fat separation coronary magnetic resonance angiography with artificial intelligence-assisted compressed sensing on coronary artery aneurysm in children with Kawasaki disease.

Translational pediatrics
2026

Lactate dehydrogenase-to-albumin ratio as a predictor of coronary artery lesions in Kawasaki disease.

Translational pediatrics
2026

Epidemiology of Kawasaki disease in the population of the Caribbean Island of Martinique, 2013-2019.

BMC pediatrics
2026

Thrombo-inflammation and Rethinking the Role of Aspirin in Kawasaki Disease.

Current rheumatology reports
2026

Preference-Informed Cluster Randomized Design for Pragmatic Clinical Trials.

Statistics in medicine
2026

Refractory Kawasaki Disease With a Coronary Artery Aneurysm in a Three-Month-Old Infant: Diagnostic Challenges and Rescue With Infliximab.

Cureus
2026

Association between the absence of individual principal clinical features and coronary artery abnormalities in complete Kawasaki disease.

Pediatric research
2026

Prognostic value of stress perfusion cardiac magnetic resonance imaging in Kawasaki disease with coronary artery aneurysms: A 10-year retrospective cohort study.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance
2026

Evaluation of coronary artery lesions in children with Kawasaki disease by coronary angiography.

BMC pediatrics
2026

Psoriasiform eruption in Kawasaki disease.

Clinical rheumatology
2026

Single-cell multi-omics sequencing reveals the immunological disturbance underlying Kawasaki disease.

Frontiers in molecular biosciences
2026

Therapeutic management of inflammatory heart diseases.

Pharmacology &amp; therapeutics
2026

Recurrent systemic inflammatory episodes with coronary artery aneurysms in an adolescent with a history of Kawasaki disease.

BMJ case reports
2025

Kawasaki Disease in Canada: The Impact of the COVID-19 Pandemic.

CJC pediatric and congenital heart disease
2025

Effect of the COVID-19 Pandemic on the Epidemiology of Kawasaki Disease in Canada.

CJC pediatric and congenital heart disease
2026

[Adult Kawasaki disease: A diagnostic case report].

Annales de pathologie
2026

The Evolving Role of Corticosteroids in Kawasaki Disease: Evidence, Mechanisms, and Clinical Implications.

Pediatric cardiology
2026

Analysis of risk factors for medium-giant coronary artery aneurysms in children with Kawasaki disease.

Cardiology in the young
2026

Biomarkers in Primary Systemic Vasculitides: Narrative Review.

International journal of molecular sciences
2026

Kikuchi-Fujimoto disease following the subacute phase of Kawasaki disease.

Pediatrics international : official journal of the Japan Pediatric Society
2025

Double Agglutination Observed in Mycoplasma-Associated Kawasaki Disease: Pathophysiological Insights and Considerations for Treatment Strategy.

Cureus
2026

Integrated metabolomic and proteomic analysis of cardiac tissues in a murine model of Kawasaki disease.

Journal of pharmaceutical and biomedical analysis
2026

Gastrointestinal Symptoms in Kawasaki Disease and Multisystem Inflammatory Syndrome in Children.

Pediatric cardiology
2026

Expression of key genes in IVIG-unresponsive Kawasaki disease and their immune correlation based on bioinformatics analysis.

Immunologic research
2026

Analysis of risk factors of coronary artery lesions in Kawasaki disease and study of IVIG treatment response.

BMC immunology
2026

Kawasaki Disease Versus Multisystem Inflammatory Syndrome in Children: Exploring the Complexities of Pediatric Cardiac Inflammatory Disorders.

Sage open pediatrics
2025

A diagnostic prediction model was established based on the clinical characteristics of multicenter children with Kawasaki disease in Xinjiang.

Frontiers in cardiovascular medicine
2025

Association Between the Persistency and Severity of Mitral Regurgitation and the Hematologic Z-Values of Inflammatory Biomarkers in Kawasaki Disease.

Korean circulation journal
2026

Kawasaki disease in adolescents: age-specific clinical features and factors associated with outcomes.

Clinical rheumatology
2025

Coronary artery abnormalities in Kawasaki disease with BCG site reactivation.

European journal of pediatrics
2026

Access to Care and Therapy for Kawasaki Disease in Morocco: A Kawasaki Disease Arab Initiative (Kawarabi) Multicenter Survey.

Pediatric cardiology
2026

Kawasaki disease and outdoor environmental stressors: a scoping review.

The Lancet regional health. Western Pacific
2026

Kawasaki disease and familial hypercholesterolemia: Their potential synergistical impact on coronary arterial vascular health and viewpoints.

Journal of clinical lipidology
2026

Lack of Discernible Benefit of High-Dose Aspirin in the Treatment of Kawasaki Disease.

Journal of the Pediatric Infectious Diseases Society
2026

[Pediatrics. Kawasaki disease].

Revue medicale suisse
2026

[Application and clinical value of cardiopulmonary exercise test in children with Kawasaki disease sequelae of giant coronary artery aneurysm].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2026

IL-33 blockade attenuates vascular inflammation in a mouse model of Kawasaki disease vasculitis.

Clinical and experimental immunology
2026

Mycoplasma pneumoniae-Induced Rash and Mucositis Presenting With Persistent Mobitz Type I Atrioventricular Block in an 8-Year-Old.

JACC. Case reports
2026

Missed Kawasaki Disease With Coronary Aneurysms and Familial Hyperlipidemia: A Case Report.

Clinical case reports
2025

Rare systemic artery lesions due to Kawasaki disease diagnosed in adults: a review of the literature on abdominal aortic aneurysms and renovascular hypertension.

Cardiology in the young
2026

Targeting osteopontin with gold nanoparticles for enhanced molecular imaging in Kawasaki disease: in-depth mechanistic study of STAT3 signaling in Col1 regulation.

Journal of translational medicine
2026

A rare cervical complication of Kawasaki disease: a retrospective study of clinical and radiological features.

Quantitative imaging in medicine and surgery
2026

Mycoplasma encephalitis, incomplete Kawasaki disease and MERS, a new association? Short communication.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
2025

How Children with Kawasaki Disease Take Acetylsalicylic Acid Mini-Tablets at Home for the Prescribed Period.

Journal of clinical medicine
2026

Subgroups of Kawasaki disease in Japanese patients and temporal change: a retrospective data-driven cluster analysis.

Clinical rheumatology
2026

Association of Coronary Vasculitis Sequelae With Atherosclerosis in Adults With a History of Kawasaki Disease: Autopsy Pathological Findings.

Arteriosclerosis, thrombosis, and vascular biology
2025

Lysophosphatidylcholine as a Novel Diagnostic Biomarker in Kawasaki Disease: Based on Immunometabolism-Related Signature.

Journal of inflammation research
2026

A nomogram based on serum CHI3L1 for predicting IVIG nonresponse in children with Kawasaki disease.

European journal of pediatrics
2026

Meta-analysis: Lipids, vascular function, cardio-cerebrovascular events after previous Kawasaki disease in children.

Journal of clinical lipidology
2026

Hepatobiliary Involvement of Kawasaki Disease Incidentally Revealed on the First Day of Illness: A Case Report.

Journal of paediatrics and child health
2026

Incomplete Kawasaki disease associated with acute icteric hepatitis and Torque teno virus infection: a case report and literature review.

BMC pediatrics
2025

Predictive value of aneurysm characteristics for one-year persistence in Kawasaki disease: a retrospective cohort study.

Frontiers in cardiovascular medicine
2025

The characteristics of the gut microbiota in patients with Kawasaki disease: a systematic review.

Frontiers in microbiology
2025

Recurrent Kawasaki Disease in a Three-Year-Old Boy: A Case Report and Review of the Literature.

Cureus
2026

Kawasaki Disease in Infancy and Long-Term Body Mass Index Trajectories.

Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates &amp; Practitioners
2025

Cardiac arrest as initial presentation of Kawasaki disease with giant coronary aneurysms: A case report and review of literature.

World journal of clinical cases
2025

A new prediction diagnosis model of incomplete Kawasaki disease based on data mining with big data.

Pediatric discovery
2025

Neurologic manifestations in Kawasaki disease and their clinical implications: a Korean nationwide pediatric cohort study.

Pediatrics and neonatology
2025

Rare Structural Variants Uncovered by Optical Genome Mapping in Multisystem Inflammatory Syndrome in Children (MIS-C).

Advanced genetics (Hoboken, N.J.)
2025

Secretory Diarrhea Caused by Activating GUCY2C Mutation in a Patient With Atypical Kawasaki Disease: A Rare Case Report.

Sage open pediatrics
2025

Clinical Practice Variation Among Pediatric Rheumatologists Treating Kawasaki Disease: Results of a North American Survey.

Children (Basel, Switzerland)
2025

Novel risk scoring system for predicting intravenous immunoglobulin resistance and coronary artery aneurysm in Thai children with Kawasaki disease.

Pediatric rheumatology online journal
2025

Clinical outcomes of giant coronary aneurysms in South Asian children with Kawasaki disease.

Pediatric rheumatology online journal
2025

Mid-Coronary Artery Wall Echogenicity Can Contribute to the Initial Diagnosis of Kawasaki Disease: Quantitative Measurements by Transthoracic Echocardiography.

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
2026

A case of trisomy 18 with Kawasaki disease.

Pediatrics international : official journal of the Japan Pediatric Society
2025

Multisystem inflammatory syndrome in children treated at a hospital in Yucatan.

Gaceta medica de Mexico
2025

Immunological Profile in Atypical Kawasaki Disease: A Case Report Highlighting the Diagnostic Utility of Cytokine Analysis by qRT-PCR.

Pediatric reports
2025

Clinical Implications of Vasculitis Associated with Familial Mediterranean Fever: A Comparative Study in Childhood.

Modern rheumatology
2025

AIM2 positively regulates B cell activation and function through the SNX9-PI3K-WASP axis.

Cell death and differentiation
2025

Early differentiation of Kawasaki disease preceded by cervical lymphadenopathy from bacterial cervical lymphadenitis.

European journal of pediatrics
2025

Long-term impaired exercise capacity and oxygen consumption in Kawasaki disease patients.

European journal of pediatrics
2025

Potential Mechanisms and Hypotheses for Pathogenic Microorganisms Triggering Kawasaki Disease.

Clinical reviews in allergy &amp; immunology
2025

Predictive value of serum lipid for kawasaki disease shock syndrome: a prospective study.

Immunologic research
2025

Infectious mononucleosis complicated with Kawasaki disease: Two case reports and literature review.

Pediatric investigation
2025

Clinical characteristics, treatments, and complications of Kawasaki disease in Peruvian children: a retrospective observational study.

Therapeutic advances in rare disease
2025

IL-10 and IL-2R as combined predictors of intravenous immunoglobulin resistance in Kawasaki disease: a retrospective cohort study.

Frontiers in immunology
2025

A prediction model for post-treatment presence of coronary artery abnormality before initial treatment in Kawasaki disease in Japan.

Frontiers in pediatrics
2025

Predictive value of blood composite ratios for Kawasaki disease and coronary artery lesions in febrile children.

Italian journal of pediatrics
2025

A case of Takayasu arteritis with advanced macrovascular lesions due to 6 years from onset to diagnosis.

Pediatrics international : official journal of the Japan Pediatric Society
2025

Pediatric rheumatic diseases and vaccinations: a promising alliance.

Frontiers in pediatrics
2025

Single-cell transcriptomic analysis reveals a systemic immune dysregulation in intravenous immunoglobulin non-responsive Kawasaki disease.

Frontiers in immunology
2025

Successful Resolution of Coronary Thrombus in a Child With Kawasaki Disease and Giant Coronary Artery Aneurysms Using Anticoagulation Therapy.

Cureus
2025

The clinical features and outcome of Kawasaki disease combined with G6PD deficiency.

Pediatric rheumatology online journal
2025

Giant Coronary Aneurysms After Delayed Diagnosis of Young Adult-Onset Kawasaki Disease.

JACC. Case reports
2025

A machine learning algorithm to predict treatment effectiveness for Kawasaki disease in China: a retrospective model development and validation study.

Frontiers in immunology
2025

Engineered microbes over immunosuppression: MAGIC as a transformative strategy for vasculitides.

Annals of medicine and surgery (2012)
2025

Development and validation of an early predictive model for coronary artery lesions in incomplete Kawasaki disease.

Translational pediatrics
2026

Stent-Free PCI With OCT-Guided Drug-Coated Balloon Angioplasty for Calcified Coronary Stenosis After Kawasaki Disease.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions
2026

Coronary artery black-blood imaging via T2-prepared phase-sensitive inversion-recovery steady-state free precession in Kawasaki disease.

Magnetic resonance imaging
2025

Bioinformatics analysis of immune-related differentially expressed genes in Kawasaki disease.

Scientific reports
2025

A Pediatric Case of Lemierre Syndrome Mimicking Kawasaki Disease.

Clinical pediatrics
2025

Normative Laboratory Value Ranges in Pediatric Patients Who Underwent Evaluation for MIS-C.

Emergency medicine international
2025

Incomplete Kawasaki Disease Mimicking Deep Neck Infection: A Case With Tracheal Deviation and Retropharyngeal Edema.

Cureus
2025

Anakinra for infants under six months with Kawasaki disease and coronary artery lesions: a multicenter case series and literature review.

Pediatric rheumatology online journal
2025

Febrile convulsion and cervical lymphadenopathy as initial presentation of incomplete node-first Kawasaki disease.

BMJ case reports
2026

Aspirin-Induced Hypersensitivity Reaction in a Child with Kawasaki Disease.

Indian journal of pediatrics
2025

The landscape of inter-institutional and multinational collaborations in Kawasaki disease.

Paediatrics &amp; child health
2025

Ferroptosis-related oxidative stress activation in the acute phase of Kawasaki disease.

Frontiers in immunology
2025

Study on the Mechanism of Aspirin Alleviating Kawasaki Disease With Coronary Artery Lesions by Inducing TRAF6 to Regulate STAT3 Ubiquitination and Inhibit Th17 Cell Differentiation.

Drug development research
2025

Clinical impact of multimodal cardiac imaging in Kawasaki disease: a prospective Kawasaki disease cardiac imaging (KDCI) cohort study with follow-up data in a Chinese population.

BMJ open
2025

Midterm cardiovascular outcomes in children with MIS-C compared to Kawasaki disease: a multicenter prospective cohort study.

Scientific reports
2025

MIS-C and Kawasaki disease: a shared spectrum of post-infectious hyperinflammation.

Pediatric research
2025

Predictive value of the combined evaluation of the neutrophil-to-lymphocyte ratio and lactate dehydrogenase level for coronary artery lesions in patients with acute Kawasaki disease.

Italian journal of pediatrics
2025

Fatal late cardiovascular sequelae of previously unrecognized Kawasaki disease in 12-year-old child.

International journal of emergency medicine
2025

HLA-DRB1*15:01 Is Associated and Linked With Kawasaki Disease, With DRB1*14:01 Conferring Risk to Coronary Artery Lesions: Case-Control and Family-Based Studies.

HLA
2025

MFG-E8 in Kawasaki Disease: Role in Endothelial Injury and Diagnostic Potential.

Journal of inflammation research
2025

Infective Endocarditis Risk After Invasive Dental Procedures.

Mayo Clinic proceedings. Innovations, quality &amp; outcomes
2025

Value of the neutrophil percentage-to-albumin ratio in predicting intravenous Immunoglobulin resistance in Kawasaki disease: a retrospective cohort study.

Italian journal of pediatrics
2025

Ethnic Differences in Juvenile Idiopathic Arthritis in the Circumpolar Region.

Children (Basel, Switzerland)
2026

Gastrointestinal Presentation at Onset or After Initial Treatment in Kawasaki Disease.

Clinical pediatrics
2026

Stress imaging in paediatric and congenital heart disease patients.

European heart journal. Cardiovascular Imaging
2025

Epidemiologic trends of Kawasaki Disease and the potential impact of COVID-19 pandemic in Shanghai from 2018 through 2022.

Chinese medical journal
2025

A case report of severe Mycoplasma pneumoniae pneumonia complicated by plastic bronchitis and Kawasaki disease.

BMC infectious diseases
2025

Establishment and Evaluation of a Candida albicans Water-Soluble Extract-Induced Murine Model of Kawasaki Disease-Associated Coronary Arteritis.

Journal of visualized experiments : JoVE
2025

Applications and challenges of paclitaxel- coated balloons beyond coronary atherosclerotic heart disease.

World journal of clinical cases
2025

Pathways and challenges in the clinical translational of radiopharmaceuticals for pediatric investigations.

Frontiers in medicine
2025

Efficacy Analysis of a 12-Cytokine Panel for the Diagnosis of Kawasaki Disease and Prediction of Intravenous Immunoglobulin Resistance.

Journal of inflammation research
2025

Meta-analysis on clinical manifestation and laboratory parameters of COVID-19-associated multisystem inflammatory syndrome in children (MIS-C).

Journal of family medicine and primary care
2025

Small kid, giant aneurysms: anakinra treatment in IVIG-resistant Kawasaki disease.

BMJ case reports
2025

Cost-effectiveness analysis of second intravenous immunoglobulin infusion versus infliximab for treating IVIG-resistant Kawasaki disease patients.

Cost effectiveness and resource allocation : C/E
2025

Therapeutic Plasma Exchange Resolves Inflammation With Increased HSD11B1 in Kawasaki Disease.

Journal of clinical apheresis
2025

Paeoniflorin Alleviates Coronary Artery Lesions in Kawasaki Disease by Activating NRF2 Pathway and Inhibiting CYP2E1 Expression.

Cardiovascular drugs and therapy
2025

Asymmetric dimethylarginine as a predictive marker for resistance to high-dose intravenous immunoglobulin in Kawasaki disease.

European journal of pediatrics
Ver todos os 7.824 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença de Kawasaki.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença de Kawasaki

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Hemolytic anemia post high-dose IVIG in Kawasaki disease: Impact of inflammation and iron status on outcomes.
    Pediatrics international : official journal of the Japan Pediatric Society· 2026· PMID 41840814mais citado
  2. [Effectiveness and safety of rivaroxaban in pediatric patients with coronary artery diseases: a case series study].
    Zhonghua er ke za zhi = Chinese journal of pediatrics· 2026· PMID 41834203mais citado
  3. Comprehensive machine learning for identifying platelet-associated diagnostic biomarkers and immune landscape in Kawasaki disease.
    Translational pediatrics· 2026· PMID 41810197mais citado
  4. Linkage between IL-23 and coronary arterial lesions in pediatric patients with Kawasaki disease.
    Frontiers in pediatrics· 2026· PMID 41809521mais citado
  5. Kawasaki disease vs. MIS-C in a child with congenital coronary artery anomaly: a case report.
    Frontiers in pediatrics· 2026· PMID 41782955mais citado
  6. Platelet-related hematologic markers and genetic associations of aspirin resistance in kawasaki disease.
    Front Mol Biosci· 2026· PMID 41994415recente
  7. Glucocorticoids in Kawasaki Disease - Refining Indications and the Science.
    N Engl J Med· 2026· PMID 41985138recente
  8. Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease.
    N Engl J Med· 2026· PMID 41985133recente
  9. Chlorogenic acid alleviates endothelial cell inflammation and apoptosis of Kawasaki disease.
    Eur J Nutr· 2026· PMID 41984219recente
  10. Development and validation of a novel interpretable machine learning model integrating immune-inflammatory indicators for intravenous immunoglobulin resistance in Kawasaki disease.
    Transl Pediatr· 2026· PMID 41982958recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:2331(Orphanet)
  2. OMIM OMIM:611775(OMIM)
  3. MONDO:0012727(MONDO)
  4. GARD:6816(GARD (NIH))
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q265936(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença de Kawasaki
Compêndio · Raras BR

Doença de Kawasaki

ORPHA:2331 · MONDO:0012727
Prevalência
Unknown
Herança
Multigenic/multifactorial
CID-10
M30.3 · Síndrome de linfonodos mucocutâneos [Kawasaki]
CID-11
Ensaios
17 ativos
Início
Adolescent, Adult, Childhood, Infancy
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0026691
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades